You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Locoregional Therapy of Locally Advanced Breast Cancer

ID: 1-19 sep 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
M. Brackstone, G.G. Fletcher, I.S. Dayes,, Y. Madarnas, S.K. SenGupta, S. Verma , Breast Cancer Disease Site Group

Patient Population

Female patients with locally advanced breast cancer (LABC).

For purposes of this guideline, LABC includes Stages IIB and IIIABC and inflammatory cancer, as defined in the AJCC Cancer Staging Manual, 6th edition. Most studies in the evidentiary base (see Section 2) included heterogeneous populations spanning Stages IIB – IIIC and sometimes included inflammatory breast cancer. Very few studies dealt only with Stage III or specific subgroups such as patients with T3N0 cancer. As most of the major studies did not report results separately for patients with Stage IIB and Stage III cancers, the evidence did not support recommendations based on a narrower definition of LABC or subdivided by stage. Although some people do not consider Stage IIB to be locally advanced, there is an increasing trend to treat less bulky disease (Stage IIB) in a similar manner, including neoadjuvant therapy; therefore, the recommendations may also be applicable to this group.

Intended Guideline Users

Surgeons, and medical and radiation oncologists specializing in breast cancer.

Research Question(s)

  1. In female patients with locally advanced breast cancer with good response to neoadjuvant therapy, what is the role of breast-conserving surgery (BCS) compared with mastectomy?
  2. a. In female patients with locally advanced breast cancer who have had a mastectomy is radiotherapy indicated?
    b. In female patients with locally advanced breast cancer does locoregional irradiation result in higher survival and lower recurrence rates compared with breast/chest wall irradiation alone?
    c. In female patients with locally advanced breast cancer and pathologically complete response to neoadjuvant therapy is radiotherapy indicated?
  3. In female patients with locally advanced breast cancer who receive neoadjuvant chemotherapy is sentinel lymph node biopsy (SLNB) or axillary dissection the most appropriate axillary staging procedure? Is SLNB indicated before neoadjuvant chemotherapy rather than at the time of surgery?
  4. How should female patients with locally advanced breast cancer who do not respond to initial neoadjuvant therapy be treated?
pdf download Summary (PDF) (365.18 Ko)